Literature DB >> 6246913

Positive interaction between agonists in the aggregation response of human blood platelets: interation between ADP, adrenaline and vasopressin.

J A Grant, M C Scrutton.   

Abstract

ADP, adrenaline and vasopressin interact positively as agonists in aggregating human blood platelets in vitro. This interaction is maximal if the addition of two of the agonists is separated by 10--20 s but decreases rapidly at longer intervals especially at low agonist concentrations. The agonist concentrations at which positive interaction gives full aggregation are significantly less than those required for such a response to each agonist alone. The lowest concentrations at which adrenaline and vasopressin interact positively are at least two orders of magnitude greater than the normal blood concentrations of these hormones, and at least an order of magnitude greater than the concentrations achieved in pathological states. Specifically antagonizing the adrenaline and ADP receptors showed that the response was to the second agonist added to the system. An inhibitor of intracellular Ca2+ movement (tetracaine) is equally effective in blocking the responses generated by a single agonist or by interaction of two agonists. Inhibitors which increase cyclic-3',5'-AMP concentration (adenosine, prostaglandin E1, dipyridamole) are more effective against the response to a single agonist than that to agonist interaction. These data suggest that positive agonist interaction results from effects on the concentrations of second messengers within the platelet rather than from a direct interaction on the membrane receptors or the transmembrane coupling mechanisms.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6246913     DOI: 10.1111/j.1365-2141.1980.tb01189.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  Effects of aspirin, dipyridamole, nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination.

Authors:  S E Akopov; E S Gabrielian
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Synergism of platelet-aggregating agents. Role of elevation of cytoplasmic calcium.

Authors:  J A Ware; M Smith; E W Salzman
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

3.  Specific correction of impaired acid hydrolase secretion in storage pool-deficient platelets by adenosine diphosphate.

Authors:  B Lages; C A Dangelmaier; H Holmsen; H J Weiss
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

4.  The direct effects of metformin on platelet function in vitro.

Authors:  R De Caterina; P Marchetti; W Bernini; R Giannarelli; D Giannessi; R Navalesi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Proceedings of the British Pharmacological Society. London, 17th-19th December, 1984. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-03       Impact factor: 8.739

6.  Activation of phospholipases A and C in human platelets exposed to epinephrine: role of glycoproteins IIb/IIIa and dual role of epinephrine.

Authors:  H S Banga; E R Simons; L F Brass; S E Rittenhouse
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Possible mechanisms of the potentiation of blood-platelet activation by adrenaline.

Authors:  M Bushfield; A McNicol; D E MacIntyre
Journal:  Biochem J       Date:  1987-02-01       Impact factor: 3.857

8.  Pairwise agonist scanning predicts cellular signaling responses to combinatorial stimuli.

Authors:  Manash S Chatterjee; Jeremy E Purvis; Lawrence F Brass; Scott L Diamond
Journal:  Nat Biotechnol       Date:  2010-06-20       Impact factor: 54.908

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.